TAO Synergies Inc.
TAOX Nasdaq Finance Services Financials FY2019βFY2025
What TAO Synergies Inc. does
No business description yet.
- Legal name
- TAO Synergies Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001104659-26-037915
0001571934
Revenue and margins
TAO Synergies Inc. had $0.3M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
TAO Synergies Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 167.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably TAO Synergies Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $34.2M | $37.5M | $30.1M | $17.7M | $5.5M |
| Current ratio | 17.8x | 29.4x | 7.1x | 17.5x | 14.0x |
| Quick ratio | 17.8x | 29.4x | 7.1x | 17.5x | 14.0x |
| Total assets | $35.5M | $38.6M | $31.1M | $17.7M | $25.8M |
| Total liabilities | $2.0M | $3.2M | $5.5M | $11.0M | $3.9M |
| Shareholders' equity | $33.5M | $32.7M | $24.3M | $5.9M | $21.1M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | 2 / 7 |
| Accruals ratio | β18.1% | β37.3% | β18.5% | 15.2% | β2.5% | β32.3% | β102.6% |
| Altman Z'' | β | β | β | β | β | β4.51 | β0.37 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | β | β | β | β | β | $0.0M | $0.3M |
| Gross profit | β | β | β | β | β | $0.0M | $0.3M |
| Research and development | $5.7M | $3.1M | $4.3M | $6.3M | $2.0M | $1.6M | $0.3M |
| Operating income | β | β | β | β | β | β$6.8M | β$9.0M |
| Pretax income | β$15.1M | β$12.7M | β$12.6M | β$5.6M | β$6.0M | β$12.8M | β$28.7M |
| Income tax | β | β | β | β | $0.0M | $0.0M | $0.0M |
| Net income | β$15.1M | β$12.7M | β$12.6M | β$5.6M | β$6.0M | β$12.8M | β$28.7M |
| Net income to common | β$15.1M | β$15.1M | β$12.6M | β$5.7M | β$13.8M | β$13.6M | β$29.1M |
| Diluted EPS | $3.01 | $12.03 | $2.51 | β$0.81 | $29.56 | β$10.99 | β$8.81 |
| Diluted shares | 0.01B | 0.00B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | |||||||
| Cash from operations | β$11.9M | β$8.1M | β$8.7M | β$11.2M | β$5.2M | β$4.9M | β$6.4M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β |
| Free cash flow | β$11.9M | β$8.1M | β$8.7M | β$11.2M | β$5.2M | β | β |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | β | β | $1.0M | $1.8M | $1.0M | $0.0M | β |
| Balance sheet | |||||||
| Cash and short-term investments | $17.4M | $5.8M | $34.2M | $37.5M | $30.1M | $17.7M | $5.5M |
| Current assets | $17.9M | $6.7M | $35.5M | $38.6M | $30.5M | $17.7M | $25.4M |
| Current liabilities | $0.5M | $1.6M | $2.0M | $1.3M | $4.3M | $1.0M | $1.8M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $17.9M | $6.8M | $35.5M | $38.6M | $31.1M | $17.7M | $25.8M |
| Total liabilities | $0.5M | $1.6M | $2.0M | $3.2M | $5.5M | $11.0M | $3.9M |
| Shareholders' equity | $17.4M | $5.1M | $33.5M | $32.7M | $24.3M | $5.9M | $21.1M |
| Margins | |||||||
| Gross margin | β | β | β | β | β | β | 87.2% |
| Operating margin | β | β | β | β | β | β | β3,024.8% |
| EBITDA margin | β | β | β | β | β | β | β3,023.6% |
| Net margin | β | β | β | β | β | β | β9,608.0% |
| Returns | |||||||
| Return on capital employed | β | β | β | β | β | β40.7% | β37.7% |
| Return on equity | β86.9% | β112.6% | β65.2% | β16.8% | β21.2% | β84.5% | β213.5% |
| Return on assets | β84.6% | β103.1% | β59.7% | β15.0% | β17.3% | β52.3% | β131.9% |
| Return on tangible equity | β86.9% | β294.4% | β37.6% | β17.4% | β56.6% | β231.2% | β138.1% |
| Growth | |||||||
| EPS growth | β | 299.7% | β79.1% | β132.3% | β | β137.2% | β |
| Share count change | β | β75.0% | 298.8% | 39.4% | β93.3% | 164.7% | 167.5% |
| Financial health | |||||||
| Current ratio | 37.3x | 4.2x | 17.8x | 29.4x | 7.1x | 17.5x | 14.0x |
| Quick ratio | 37.3x | 4.2x | 17.8x | 29.4x | 7.1x | 17.5x | 14.0x |
| Quality scores | |||||||
| Piotroski F-score | β | β | β | β | β | β | 2.0 |
| Altman Z'' | β | β | β | β | β | β4.5 | β0.4 |
| Accruals ratio | β18.1% | β37.3% | β18.5% | 15.2% | β2.5% | β32.3% | β102.6% |
Source: SEC EDGAR XBRL filings (CIK 0001571934). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.